CA2360326C - Use of 4-amino pyridine for treatment of peripheral neuropathies - Google Patents

Use of 4-amino pyridine for treatment of peripheral neuropathies Download PDF

Info

Publication number
CA2360326C
CA2360326C CA2360326A CA2360326A CA2360326C CA 2360326 C CA2360326 C CA 2360326C CA 2360326 A CA2360326 A CA 2360326A CA 2360326 A CA2360326 A CA 2360326A CA 2360326 C CA2360326 C CA 2360326C
Authority
CA
Canada
Prior art keywords
nervous system
treatment
subject
peripheral
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2360326A
Other languages
English (en)
French (fr)
Other versions
CA2360326A1 (en
Inventor
Jay M. Meythaler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of CA2360326A1 publication Critical patent/CA2360326A1/en
Application granted granted Critical
Publication of CA2360326C publication Critical patent/CA2360326C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2360326A 1999-02-09 2000-02-09 Use of 4-amino pyridine for treatment of peripheral neuropathies Expired - Lifetime CA2360326C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11927399P 1999-02-09 1999-02-09
US60/119,273 1999-02-09
PCT/US2000/003396 WO2000047210A1 (en) 1999-02-09 2000-02-09 Use of 4-amino pyridine for treatment of peripheral neuropathies

Publications (2)

Publication Number Publication Date
CA2360326A1 CA2360326A1 (en) 2000-08-17
CA2360326C true CA2360326C (en) 2011-04-05

Family

ID=22383494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2360326A Expired - Lifetime CA2360326C (en) 1999-02-09 2000-02-09 Use of 4-amino pyridine for treatment of peripheral neuropathies

Country Status (10)

Country Link
US (1) US6503931B1 (cg-RX-API-DMAC7.html)
EP (1) EP1152760B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002536413A (cg-RX-API-DMAC7.html)
AT (1) ATE357914T1 (cg-RX-API-DMAC7.html)
AU (1) AU3360000A (cg-RX-API-DMAC7.html)
CA (1) CA2360326C (cg-RX-API-DMAC7.html)
DE (1) DE60034110T2 (cg-RX-API-DMAC7.html)
DK (1) DK1152760T3 (cg-RX-API-DMAC7.html)
ES (1) ES2284485T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000047210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820423B1 (fr) * 2001-02-05 2005-12-02 Assist Publ Hopitaux De Paris Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US9993429B2 (en) 2013-03-15 2018-06-12 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
MA35698B1 (fr) * 2013-05-16 2014-12-01 Univ Mohammed V Souissi Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
WO2024011220A1 (en) 2022-07-08 2024-01-11 University Of Rochester Potassium channel blockers or derivatives thereof for preventing, alleviating, and/or treating tissue dysfunction caused by toxic insults

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) * 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition

Also Published As

Publication number Publication date
EP1152760B1 (en) 2007-03-28
DK1152760T3 (da) 2007-07-30
EP1152760A4 (en) 2005-03-23
DE60034110D1 (de) 2007-05-10
WO2000047210A1 (en) 2000-08-17
ATE357914T1 (de) 2007-04-15
JP2002536413A (ja) 2002-10-29
ES2284485T3 (es) 2007-11-16
US6503931B1 (en) 2003-01-07
CA2360326A1 (en) 2000-08-17
AU3360000A (en) 2000-08-29
DE60034110T2 (de) 2007-12-06
EP1152760A1 (en) 2001-11-14

Similar Documents

Publication Publication Date Title
Devinsky et al. Safety of intravenous valproate
Deangelis et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non‐hodgkin's lymphoma
JP3758164B2 (ja) 筋萎縮性側索硬化症(als)治療剤
TWI477273B (zh) 低頻率格拉替雷(glatiramer)醋酸鹽之治療
US10537566B2 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
Nuver-Zwart et al. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.
US20090105298A1 (en) Pharmaceutical composition for therapy of interstitial cystitis
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
US12318380B2 (en) Treatment of demyelinating diseases
US20240041811A1 (en) Methods of treatment using an mtorc1 modulator
TW201010703A (en) Methods of using sustained release aminopyridine compositions
US6503931B1 (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
KR20120050512A (ko) 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료
US20210023074A1 (en) Treatment of demyelinating diseases
EP3509583B1 (en) Estrogen receptor ligands, compositions and methods related thereto
US20050059709A1 (en) Treatment of a neuropathy with rapid release aminopyridine
CN117956959A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
US20050192321A1 (en) Treatment of neuropathy with rapid release aminopyridine
WO2014182944A1 (en) Compositions and method for treatment of ischemic neuronal reperfusion injury
US20260097008A1 (en) Acetyl leucine for use in treating niemann-pick disease type c
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
EA052491B1 (ru) Способы лечения субъектов с абдоминальным ожирением, гипертриглицеридемией и/или нарушением уровня глюкозы
JPH0737387B2 (ja) 神経系症状の処置剤
CN118695856A (zh) 用于治疗与中枢性通气不足相关的疾患的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200210